Immunotherapy: Towards on early non-small cell lung cancer / 医学研究生学报

ABSTRACT

Surgery is the standard treatment for early resectable non-small cell lung cancer (NSCLC), but the recurrence rate is high. There is no effective cure for this. Immunological checkpoint inhibitors have altered the therapeutic model of patients with advanced gene therapy for advanced NSCLC, presenting new hope for early immunotherapy of NSCLC. Immunological checkpoint inhibitors have altered the therapeutic model of patients with driving gene-negative NSCLC patients, presenting new hope for early immunotherapy of NSCLC. Based on the analysis of the status of early NSCLC adjuvant therapy, the clinical study of immunological checkpoint inhibitors as a new adjuvant/adjuvant therapy in early operable NSCLC was explored in this paper.